Nevertheless, 89Zr-trastuzumab has the potential to characterize the whole body HER2 status of all the tumor and metastatic sites thus obviating repeated tissue biopsies to assess the intrapatient heterogeneity. Here, ERBB2 is linked to neoplasm.